Krawczyk et al., 2011 - Google Patents
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virusKrawczyk et al., 2011
View PDF- Document ID
- 743000783024781199
- Author
- Krawczyk A
- Krauss J
- Eis-Hübinger A
- Däumer M
- Schwarzenbacher R
- Dittmer U
- Schneweis K
- Jäger D
- Roggendorf M
- Arndt M
- Publication year
- Publication venue
- Journal of virology
External Links
Snippet
Herpes simplex virus (HSV) glycoprotein B (gB) is an integral part of the multicomponent fusion system required for virus entry and cell-cell fusion. Here we investigated the mechanism of viral neutralization by the monoclonal antibody (MAb) 2c, which specifically …
- 108010045030 monoclonal antibodies 0 title abstract description 150
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krawczyk et al. | Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus | |
| Planchais et al. | Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA. 1 and BA. 2 | |
| Kruse | Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China | |
| JP6722233B2 (en) | Anti-HSV antibody | |
| Benhnia et al. | Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement | |
| Zhang et al. | Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion | |
| JP6483337B2 (en) | Human monoclonal antibody having specificity for dengue virus serotype 1 E protein and use thereof | |
| US20180071389A1 (en) | Monoclonal Antibodies for Ebola and Marburg Viruses | |
| JP6649284B2 (en) | External application of anti-HSV antibody | |
| Wu et al. | Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants | |
| Du et al. | A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus | |
| Wang et al. | Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1 | |
| Li et al. | Monoclonal antibody against EV71 3Dpol inhibits the polymerase activity of RdRp and virus replication | |
| TWI695720B (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition | |
| Tian et al. | A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D | |
| He et al. | Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody | |
| Shcheblyakov et al. | Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection | |
| Fernandez-Sesma et al. | A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro | |
| WO2024256623A1 (en) | Novel anti-hsv antibody | |
| Nejatollahi et al. | Neutralizing human single-chain antibodies against herpes simplex virus type 1 glycoprotein D from a phage display library | |
| Geoghegan | Identification and Applications of Llama-Derived Single Domain Antibodies Binding to Glycoprotein D of Herpes Simplex Virus 2 | |
| HK1236038A1 (en) | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |